Bio Break: Why the Design History File (DHF) Matters in Medtech
When developing a medical device, documentation isn’t just a regulatory checkbox, it’s a fundamental tool for ensuring safety, traceability, and successful market entry. At the center of this documentation is an important file, the Design History File (DHF).
In this episode of Bio Break, Nick and Joris break down what a DHF is, why it’s required, and how it plays a vital role throughout the development lifecycle. A DHF includes all design documents created during development, such as product requirements, risk assessments, and verification reports. It’s the formal record that regulatory bodies like the FDA review to ensure a device was designed according to sound engineering practices and quality system procedures within the Design History File framework.
The conversation dives into why clients sometimes view DHFs as a burden, especially in the early stages of innovation where rapid iteration is key. To address this, StarFish Medical takes a two-phase approach. Initially, they prioritize flexibility and creative ideation. Small teams use light tools to explore feasibility, test concepts, and gain confidence before formal documentation begins. At this stage, they start gathering elements crucial to a comprehensive Design History File.
This approach helps teams avoid premature overhead while still aligning with regulatory expectations. It also ensures that once a device is ready for submission, the documentation is accurate, thorough, and aligned with the product’s risk profile and intended use, ultimately contributing to a successful completion of the Design History File.
Whether you’re a startup innovator or part of a large MedTech team, this episode offers a clear explanation of how design documentation supports both development and regulatory success, without derailing early creativity, and highlights the importance of the Design History File.
Learn more about StarFish Medical.
Related Resources
Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.
Nigel Syrotuck breaks down the realistic medical device V&V cost and schedule for terminally sterilized devices, picking up after design freeze and walking through each major phase of the process.